FDA flags quality issues with Eli Lilly plant that makes its COVID-19 antibody drug

In a memo dated Oct. 2, FDA compliance officers stated that findings from a four-week evaluation of the plant, which is located in Branchburg, N.J., “support a major failure of quality guarantee.”.

FDA inspectors discovered quality control concerns with an Eli Lilly plant in New Jersey that makes a COVID-19 antibody drug the company has actually asked for emergency situation use authorization for, Bloomberg reported..

The FDA examination officers suggested that Eli Lilly receive a caution letter relating to the plants quality control problems, which is one of the FDAs strongest enforcement measures..

The inspectors also said Eli Lilly workers at the plant consistently bypassed testing systems. The events “leave space for substantial potential effect on product quality,” they wrote..

Eli Lilly informed Bloomberg it believes the problems raised by the inspectors wont impact drug quality or client safety and said it is working to address them..

Read the full short article here..

” The concerns raised during the Branchburg evaluations have our full attention, and we have been working carefully with the FDA on removal efforts,” the company told Bloomberg..

Eli Lilly said it hasnt got a warning letter or any other enforcement letters about the plant from the FDA..

A cautioning letter from the FDA might slow Eli Lillys strategy to have 1 million dosages of the COVID-19 antibody drug ready by the end of the year. The New Jersey branch is among 5 websites around the world where Eli Lilly is making the drug, which it has actually named bamlanivimab, according to Bloomberg..

Maia Anderson –
Thursday, October 22nd, 2020
Print|Email.

The officers stated they feel it is “essential that FDA do something about it,” Bloomberg reported..

In one event described by the inspectors, an Eli Lilly staff member presumably utilized the incorrect material in a vital purification action. In another, regular checks exposed a potential impurity in a drug, however the employee retested it to get a passing result instead of trying to determine why there were indications of a pollutant, Bloomberg reported..

More posts on pharmacy:7 procedures health centers, drugmakers are taking to avoid COVID-19 vaccine thefts12 drugs being checked as COVID-19 treatmentsParticipant in AstraZenecas Brazil COVID-19 trial who passed away didnt get vaccine.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.